Pramipexole increases vesicular dopamine uptake: Implications for treatment of Parkinson's neurodegeneration

European Journal of Pharmacology

Volumn 474, Issue 2-3, 2003, Pages 223-226

  Truong, Jannine G ^a   Rau, Kristi S ^a   Hanson, Glen R ^a   Fleckenstein, Annette E ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Eticlopride; Parkinson's disease; Pramipexole; Vesicle function; Vesicular monoamine transporter

Indexed keywords

CARRIER PROTEIN; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ETICLOPRIDE; PRAMIPEXOLE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE UPTAKE; DRUG EFFECT; DRUG MECHANISM; IMMUNOREACTIVITY; MALE; NERVE DEGENERATION; NERVE ENDING; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; RAT; SYNAPSE VESICLE; TISSUE DISTRIBUTION;

EID: 0142070767     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)02080-6     Document Type: Article

References (28)

1. Bauerfeind R., Galli T., De Camilli P. Molecular mechanisms in synaptic vesicle recycling. J. Neurocytol. 25:1996;701-715.
2. Bennett J.P., Piercey M.F. Pramipexole - a new dopamine agonist for the treatment of Parkinson's disease. J. Neurol. Sci. 163:1999;25-31.
3. Brown J.M., Hanson G.R., Fleckenstein A.E. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J. Pharmacol. Exp. Ther. 296:2000;762-767.
4. Brown J.M., Riddle E.L., Sandoval V., Weston R.K., Hanson J.E., Crosby M.J., Ugarte Y.V., Gibb J.W., Hanson G.R., Fleckenstein A.E. A single methamphetamine administration rapidly decreases vesicular dopamine uptake. J. Pharmacol. Exp. Ther. 302:2002;497-501.
5. Cassarino D.S., Fall C.P., Smith T.S., Bennett J.P. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion. J. Neurochem. 71:1998;295-301.
6. Cubells J.F., Rayport S., Rahendran J. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 14:1994;2260-2271.
7. Ferger B., Teismann P., Mierau J. The dopamine agonist pramipexole scavenges hydroxyl free radicals induced by striatal application of 6-hydroxydopamine in rats: an in vivo microdialysis study. Brain Res. 883:2000;216-223.
8. Fleckenstein A.E., Metzger R.R., Wilkins D.G., Gibb J.W., Hanson G.R. Rapid and reversible effects of methamphetamine on dopamine transporters. J. Pharmacol. Exp. Ther. 282:1997;834-838.
9. Fumagalli F., Gainetdinov R.R., Wang Y.M., Valenzano K.J., Miller G.W., Caron M.G. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J. Neurosci. 19:1999;2424-2431.
10. Hall E.D., Andrus P.K., Oostveen J.A., Althaus J.S., VonVoigtlander P.F. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res. 742:1996;80-88.
11. Hogan K.A., Staal R.G., Sonsalla P.K. Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations. J. Neurochem. 74:2000;2217-2220.
12. Hubble J.P. Pre-clinical studies of pramipexole: clinical relevance. Eur. J. Neurol. 7:2000;15-20.
13. Jenner P., Olanow W.C. Understanding cell death in Parkinson's disease. Ann. Neurol. 44:1998;S72-S82.
14. LaVoie M.J., Hastings T.G. Dopamine quinine formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J. Neurosci. 19:1999;1484-1491.
15. Miller G.W., Gainetdinov R.R., Levey A.I., Caron M.G. Dopamine transporters and neuronal injury. Trends Pharmacol. Sci. 20:1999;424-429.
16. Pramipexole vs. levodopa as initial treatment for Parkinson disease. JAMA. 284:2000;1931-1973.
17. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. JAMA. 287:2002;1653-1661.
18. Piercey M.F. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin. Neuropharmacol. 21:1998;141-151.
19. Richard D.A., Guatimosim C., Betz W.J. Two endocytic recycling routes selectively fill two vesicle pools in frog nerve terminals. Neuron. 27:2000;551-559.
20. Riddle E.L., Topham M.K., Haycock J.W., Hanson G.R., Fleckenstein A.E. Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur. J. Pharmacol. 449:2002;71-74.
21. Sandoval V., Riddle E.L., Hanson G.R., Fleckenstein A.E. Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors. J. Neurosci. 22:2002;8705-8710.
22. Sandoval V., Riddle E.L., Hanson G.R., Fleckenstein A.E. Methylphenidate alters vesicular monamine transport and prevents methamphetamine-induced dopaminergic deficits. J. Pharmacol. Exp. Ther. 304:2003;1181-1187.
23. Schmitz Y., Lee C.J., Schmauss C., Gonon F., Sulzer D. Amphetamine distorts stimulation-dependent dopamine overflow: effects on D2 autoreceptors, transporters, and synaptic vesicle stores. J. Neurosci. 21:2001;5916-5924.
24. Sethy V.H., Wu H., Oostveen J.A., Hall E.D. Neuroprotective effects of the dopamine agonist pramipexole and bromocriptine in 3-acetylpyridine-treated rats. Brain Res. 754:1997;181-186.
25. Sudhof T.C. The synaptic vesicle cycle revisited. Neuron. 28:2000;317-320.
26. Sulzer D. Alpha-synuclein and cytosolic dopamine: stabilizing a bad situation. Nat. Med. 7:2001;11869-11874.
27. Sun A.Y., Chen Y.M. Oxidative stress and neurodegenerative disorders. J. Biomed. Sci. 5:1998;401-414.
28. 3H]dopamine uptake. J. Pharmacol. Exp. Ther. 280:1997;1432-1444.